EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Concomitant use of dupilumab with glucocorticoid in bullous pemphigoid reduces disease severity: A preliminary study

Lingyu Hu, Ruiting Huang, Fuqiong Jiang iD, Shuqiong You, Qian Wu

Immunity, Inflammation and Disease · 2023

DOI: 10.1002/iid3.924 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, 2023. Verfasst von Lingyu Hu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China. Hauptthemen laut MEDLINE: Pemphigoid, Bullous. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To retrospectively analyze the efficacy and safety of dupilumab in the treatment of bullous pemphigoid.

Methods

From October 2020 to October 2022, the medical records of patients with bullous pemphigoid who were treated with dupilumab in our department were collected retrospectively to analyze the therapeutic effect and changes in laboratory indexes.

Results

The records of a total of 11 patients with bullous pemphigoid who were treated with dupilumab was reviewed. Within 2 weeks of the treatment, 10 (90.9%) of the 11 patients had complete or substantial control of the disease. The BPDAI scores of the patients decreased from baseline 113 (62, 181) to 37 (6, 130) at 2 weeks ( p = .001) and 4 (0, 37) at 12 weeks after treatment ( p < .001). In the 11 patients treated with dupilumab, the relief time of pruritus was 0–3 days (0.5, 7) days, and the pruritus was significantly alleviated after 2 weeks ( t = 15.925, p < .001). The DLQI score decreased from (25.5 ± 2.5) before treatment, to (11.8 ± 4.4) at 2 weeks ( t = 10.764, p < .001) and (2.1 ± 1.9) at 12 weeks ( t = 30.038, p < .001). The patients had high eosinophil counts, high serum IgE levels, low serum total protein levels, and abnormal blood coagulation function. The aforementioned indicators gradually returned to normal after treatment. No adverse reactions occurred during the treatment.

Conclusion

Dupilumab can effectively control the condition of bullous pemphigoid, efficiently relieve pruritus symptoms, and is relatively safe.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pemphigoid, BullousHumansGlucocorticoidsRetrospective StudiesPruritusPatient AcuityAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

IL-13IL-4blood coagulation functiondupilumab biologicseosinophilsimmunoglobulin Epemphigoidtreatment

Substanzen

GlucocorticoidsdupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Dermatology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.

ORCID-Profile: Fuqiong Jiang

Zitieren

APA

Hu, L., Huang, R., Jiang, F., You, S., & Wu, Q. (2023). Concomitant use of dupilumab with glucocorticoid in bullous pemphigoid reduces disease severity: A preliminary study. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.924

Vancouver

Hu L, Huang R, Jiang F, You S, Wu Q. Concomitant use of dupilumab with glucocorticoid in bullous pemphigoid reduces disease severity: A preliminary study. Immunity, Inflammation and Disease. 2023. doi:10.1002/iid3.924

BibTeX
@article{Hu2023,
  author = {Hu, Lingyu and Huang, Ruiting and Jiang, Fuqiong and You, Shuqiong and Wu, Qian},
  title = {Concomitant use of dupilumab with glucocorticoid in bullous pemphigoid reduces disease severity: A preliminary study},
  journal = {Immunity, Inflammation and Disease},
  year = {2023},
  doi = {10.1002/iid3.924}
}
Kostenlos starten →